Focused On-demand Library for Integrator complex subunit 6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UL03

UPID:

INT6_HUMAN

Alternative names:

DBI-1; Protein DDX26; Protein deleted in cancer 1

Alternative UPACC:

Q9UL03; Q0P664; Q6PJP4; Q9UFK0; Q9Y5M9

Background:

Integrator complex subunit 6 (Integrator complex subunit 6), also known as DBI-1, Protein DDX26, and Protein deleted in cancer 1, plays a crucial role in the transcription and processing of small nuclear RNAs (snRNA) U1 and U2. It is part of the Integrator complex, associated with RNA polymerase II, and is involved in recruiting cytoplasmic dynein to the nuclear envelope. Its potential tumor suppressor function, highlighted by its ability to suppress tumor cell growth, underscores its biological significance.

Therapeutic significance:

Understanding the role of Integrator complex subunit 6 could open doors to potential therapeutic strategies, especially considering its tumor suppressor capabilities and involvement in fundamental cellular processes.